JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $185

Benzinga Newsdesk www.benzinga.com Positive 86.6%

Neg 0% Neu 0% Pos 86.6%

JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $177 to $185.